Latest enhancements save time and resources and help prevent data errors.
LENEXA, Kan., May 4, 2016 Mediware Information Systems, Inc. has released Transtem™ Patient 2016, a powerful cellular therapy software application that helps blood and marrow transplant (BMT) programs meet compliance and accreditation standards while providing life-saving treatments to patients.
Since Transtem’s initial launch, Mediware has continued to enhance core application features. These enhancements are designed to help BMT programs increase efficiency, maintain regulatory compliance and improve the way data is accessed and analyzed—all to support the goal of improving patient outcomes.
The Transtem Patient 2016 product release continues to build on these efforts with several significant enhancements. Among the most important of these is a more streamlined process for managing reporting to external organizations such as the Center for International Blood and Marrow Transplant Research (CIBMTR). This is achieved with increased auto-population of forms. This feature nearly eliminates duplicate data entry, saving countless hours of staff time while also minimizing errors, improving data integrity and driving timely reporting and compliance. The Transtem system is AGNIS-certified for the electronic transmission of all currently accepted CIBMTR form versions.
In addition, enhancements have been made to support reporting to third-party payers through the automation of RFI reports in compliance with the standards set forth by the American Society for Blood and Marrow Transplantation (ASBMT). This critical feature allows BMT programs to produce reports in a matter of minutes rather than days.
The 2016 software release also includes a more robust offering for custom report writing, to help customers make their data actionable. By continuing to leverage Microsoft SQL Server Reporting Services (SSRS) as the integrated analytics engine, Mediware is enabling BMT programs to analyze real-time data on demand. This supports internal and external reporting needs, program analysis, and quality assurance metrics while also driving research initiatives—all through a user-friendly interface.
“Now, BMT programs can view and analyze their data when and how they need it, which supports improved communication and decision-making processes and, ultimately, better patient management,” said Thomas Mann, Mediware’s president and CEO.
“Transtem 2016 is another step forward in Mediware’s goal of delivering comprehensive, integrated technology for the management of BMT programs and patients,” explained Jonathan Wofford, Transtem product manager. “The increased auto-population of the CIBMTR forms is one example of how we can leverage technology to support critical, time-consuming tasks so transplant teams can maintain their focus on caring for patients,” he added.
About Mediware Information Systems
Mediware is a leading provider of specialized healthcare software with more than four decades of experience developing and delivering innovative solutions designed to improve efficiencies and address safety concerns. Transtem was designed by cellular therapy professionals to provide a comprehensive solution for cell therapy labs, cord blood banks, transplant centers and academic medical centers to collect, process, transfuse and track adult and cord blood stem cells used in the treatment of cancer and blood-related diseases. Transtem’s unique capabilities combine a focus on donors, products and patients to provide a 360-degree view of treatments and outcomes.